Citations

Showing 10 of 108162 citations.

Use of Remdesivir in Myasthenia gravis and COVID‐19
Peters, Bradley J. , DuBrock, Hilary M. , Rabinstein, Alejandro A.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | April 9, 2021 | Volume: 41 | Issue: 6 | Pages: 546-550

10.1002/phar.2524 | PMID 33835512 Get It

AbstractMyasthenia gravis and the associated pharmacologic management options could place patients at higher risk of contracting severe acute respiratory syndrome coronavirus 2 and exhibiting more severe manifestations of the novel coronavirus disease 2019 (COVID‐19). Multiple agents have been studied for the management of the COVID‐19, including remdesivir. To date, no published reports have evaluated the utilization of the antiviral remdesivir in patients with myasthenia gravis. We describe the first reported clinical course of three patients with myasthenia gravis who safely received remdesivir in combination with dexamethasone for the management of COVID‐19.
Stress, Resilience, and Coping of Healthcare Workers during the COVID-19 Pandemic
Croghan, Ivana T. , Adusumalli, Jayanth , Beck, Elizabeth W., Ghosh, Karthik, Schroeder, Darrell R. , Bhagra, Anjali , Chesak, Sherry S. , Schroeder, Darrell , Fischer, Karen M. , Patel, Shruti

Mayo Clinic

Journal of Primary Care & Community Health | April 9, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211008448 | PMID 33834900 Get It

Objective To estimate the health care workers (HCWs) self-reported stress, resilience, and coping during the COVID-19 pandemic, and to determine inter-professional differences. Participants and Methods An email survey was sent to 474 HCW at a Midwestern HealthCare facility between April 9, 2020 and April 30, 2020. A total of 311 (65.6%) responses were received by May 31, 2020. The survey utilized 3 validated instruments: Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), Brief Resilience Coping Scale (BRCS). Results Of the 311 responses, 302 were evaluated: 97 from nonmedical staff with patient contact (NMPC); 86 from nonmedical staff with no patient contact (NMNPC); 62 from medical doctors (MD), physician assistants (PA) and nurse practitioners (NP); and 57 from nurses. Significant differences were noted across job categories for stress and resilience, with nurses reporting highest PSS scores (effect estimates: −2.72, P = .009 for NMNPC; −2.50, P = .015 for NMPC; −3.21, P = .006 for MD/NP/PA respectively), and MD/NP/PA group with highest BRS scores: nurses (−0.31, P = .02); NMPC (−0.3333, P = .01); and NMNPC (−0.2828, P = .02). Younger personnel had higher stress (−1.59 per decade of age, P < .01) and more resilience (0.11 per decade of age, P = .002). Conclusion These self-reported data indicate that MD/NP/PA had the highest resilience scores and the nurses had highest stress levels. Efforts are warranted to include all HCWs in systematic stress mitigating interventions with particular attention to understand specific factors contributing to stress for the nursing team.
ELASTASE-2 KNOCKOUT IS ASSOCIATED WITH LESS SUSCEPTIBLE AORTA DILATION IN RESPONSE TO ANGIOTENSIN II STIMULATION IN THE MICE MODEL
Mestriner, Fabíola , Mesquita, Carolina D’ Avila, Couto, Ariel Emiliano Souza do, Campos, Ligia Borges, Barbosa, Jessyca Michelon, Corsi, Carlos Alexandre Curylofo , Nakagi, Vanessa Souza, Polonis, Kataryzina, Ribeiro, Maurício Serra , Mesquita, Carolina D Avila, Couto, Ariel E.S., Joviliano, Edwaldo Édner , Évora, Paulo Roberto Barbosa , Becari, Christiane

Mayo Clinic

Journal of Hypertension | April 9, 2021 | Volume: 39 | Issue: Supplement 1 | Pages: e352-e353

10.1097/01.hjh.0000748612.06795.2b Get It

Objective: Elastase-2 (ELA-2), a chymotrypsyn-serine protease elastase family member 2A, is expressed in several tissues such as the lungs, heart, liver, kidneys, brain, and vessels. ELA-2 was found to generate angiotensin II (AngII) in arteries and contribute to resistance arteries and vascular remodeling in animal models. It has also been shown that continuous infusion of AngII induces abdominal aortic aneurysm (AAA) in mice. Therefore, we sought to investigate the role of ELA-2 in an aortic dilation, which is a risk factor to AAA development, in a mouse model. Design and method: Male wild type (C57bl/6, WT) and ELA-2 knockout (CELA-2aTm1Bdr; ELA-2 KO) mice were treated with saline or angiotensin II (AngII, 2.28 g/g/min) for twenty-eight days by subcutaneously mini-pumps infusion. To evaluate the role of elastase-2 in a AAA development, mice were divided into four groups: WT treated with saline (WT+SAL), ELA-2KO treated with saline (ELA-2KO+SAL), WT treated with AngII (WT+AngII), and ELA-2KO treated with Ang II (ELA-2KO+AngII). The vascular ultrasound (US) was done before treatment and once a week during 28 days of treatment. The abdominal aorta measurements such as maximum aortic diameter, aortic para-renal diameter, aortic infra-renal diameter, and aortic supra-renal diameter were collected. A dilated aorta is a risk factor aortic rupture/aneurysm. Statistical analyses were performed by the Shapiro Wilk Normality test, two-way ANOVA with Sidak's multiple comparisons test. This study is approved by the Ethics Committee (CEUA-131/2019). Results: The most dilated aorta as measured by the maximum aorta diameter was detected in WT+AngII group and was 60% higher than in the WT+Saline (p = 0.01). There was no significant difference in the maximum aorta diameter between ELA-KO+SAL vs. ELA-2KO+AngII (p = 0.8). The measurement of dilation in aortic para-renal and aortic infra-renal showed that AngII induced a dilation in WT+AngII (p < 0.05), while not modified these parameters in ELA-2KO+AngII group. The aortic supra-renal diameter parameters and weight showed no differences between groups. Conclusions: These results suggest that ELA-2KO mice might be less susceptible to develop an aorta dilation. Therefore, Elastase-2 is a candidate factor that contributes to the formation and/or development of abdominal aortic aneurysm.
GENETIC ASSOCIATION STUDIES OF FIBROMUSCULAR DYSPLASIA IDENTIFY NEW RISK LOCI AND SHARED GENETIC BASIS WITH MORE COMMON VASCULAR DISEASES
Yang, Min‐Lee , Ma, Lijiang , Sengupta, Sebanti, Hunker, Kristina L. , Lorthioir, Aurélien , Gornik, Heather L. , Januszewicz, Andrzej , Jeunemaı̂tre, Xavier , Georges, Adrien , Berrandou, Takiy-Eddine , Bakker, Mark K. , Dikilitas, Ozan , Satterfield, Benjamin A. , Amar, Laurence , Prejbisz, Aleksander , Pappaccogli, Marco , Ruigrok, Ynte M. , Olin, Jeffrey W. , Rietzschel, Ernst R. , Celinska, Ewa Warchol , Kullo, Iftikhar J. , Azizi, Michel , Persu, Alexandre , Kovacic, Jason C. , Ganesh, Santhi K. , Bouatia‐Naji, Nabila

Mayo Clinic

Journal of Hypertension | April 9, 2021 | Volume: 39 | Issue: Supplement 1 | Pages: e267

10.1097/01.hjh.0000747516.63267.65 Get It

Abstract Objective: Fibromuscular dysplasia (FMD) is an arteriopathy that presents mainly by hypertension, stroke or dissection. Diagnosis is often made in middle-aged women with few cardiovascular risk factors. We aim at identifying common genetic variants associated to FMD. Design and method: We tested ∼6.5 million common genetic variants (MAF > 0.01) in 1962 cases and 7100 controls from 6 studies using variants and gene-based association analyses. Participants were of European ancestry, with similar characteristics (91% multifocal, 88% women), diagnosis methods and inclusion/exclusion criteria. Transcriptome-wide association (TWAS), eQTL, gene expression by sex and colocalization analyses used expression data in arteries from GTEx and/or FMD patients and matched controls. Open chromatin regions were defined using ATAC-Seq on primary human fibroblasts, smooth muscle and endothelial cells. Genetic correlations were assessed using summary statistics from UKBiobank and/or published studies by linkage disequilibrium score regression and multi-trait-based conditional and joint analyses (mtCOJO). Results: We confirmed the previously identified PHACTR1 locus and identified three new loci (LRP1, ATP2B1, and LIMA1) associated with FMD. TWAS in arteries identified one additional locus (SLC24A3). Through integration of annotation datasets, we provided prioritization of variants and genes. These are consistently and specifically expressed in fibroblasts, smooth muscle cells, and arterial tissues. PHACTR1 and SLC24A3 showed sex differences in gene expressions consistent with the direction of effects of FMD risk alleles. FMD genes are involved in regulatory mechanisms related to actin cytoskeleton and intracellular calcium homeostasis, two mechanisms central to vascular contraction. We found significant genetic overlaps between FMD and blood pressure traits, for the associated loci and globally at the genome level, but demonstrated that hypertension is not driving the genetic association with FMD. We also found positive genetic correlations with migraine and intracranial aneurysm, and an inverse correlation with coronary artery disease, independently from the genetics of blood pressure. Conclusions: We describe robustly associated loci and genes with FMD and provide several new leads toward understanding biological mechanisms of stenosis and dissection in young women in the absence of atherosclerosis, which shares part of its genetic basis with more common cardiovascular and neurovascular diseases.
A case of metachronous bilateral secretory carcinoma
Burlile, Jessica F. , Collins, Andrea , García, Joaquín J. , Gendron, Kristin, Cunningham, Danielle, Foote, Robert L. , Burlile, Jessica , Garcia, Joaquin

Mayo Clinic

Rare Tumors | April 9, 2021 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/20363613211009144 | PMID 33889375 Get It

Secretory carcinoma (SC) was first recognized as a distinct salivary malignancy in 2010. In the nine years since its recognition, there have been multiple reports of SC of the major and minor salivary glands, as well one case of tongue base involvement. Here we present the first reported case of bilateral SC. The first tumor, diagnosed before the recognition of SC, was classified as mucoepidermoid carcinoma. After the contralateral parotid tumor was diagnosed as SC in 2016, the two histologies were compared, and the mucoepidermoid carcinoma was reclassified as SC. In this report, we describe our patient’s clinical course and review the SC literature, with a focus on pathologic diagnosis and clinical prognosis.
NOVEL MIRNAS AS TARGETS OF MESENCHYMAL STEM CELLS-BASED THERAPY FOR TREATMENT OF PREECLAMPSIA
Todd, Naomi, Hunter, Alyson, McCance, David R., Ali, Ahlam, McClements, Lana , Alqudah, Abdelrahim , Šuvakov, Sonja , Richards, Claire , Eastwood, Kelly‐Ann , Holmes, Valerie A , Young, Ian Stuart , Furlong, Fiona M. , Krasnodembskaya, Anna , López–Campos, Guillermo , Garovic, Vesna D.

Mayo Clinic

Journal of Hypertension | April 9, 2021 | Volume: 39 | Issue: Supplement 1 | Pages: e26-e27

10.1097/01.hjh.0000744632.79980.c9 Get It

Objective: Preeclampsia is a cardiovascular complication characterised by the new onset of hypertension and proteinuria or other end-organ dysfunction. Currently there are no effective treatments for preeclampsia except delivery of the placenta and the baby, often pre-term. Administration of mesenchymal stem cells (MSCs) has shown therapeutic potential in pre-clinical models of preeclampsia. In this study, we aimed to identify novel placental miRNAs in preeclampsia which could be targeted by MSCs or their extracellular vesicles (MSC-EVs). Design and method: Human MSCs were isolated from abdominal fat tissue during caesarean section and cultured for 48 h. Human umbilical cord endothelial cells (HUVEC) were co-cultured with MSCs from pregnancies with or without preeclampsia (n = 3) up to 90 h and angiogenesis assessed using tubule formation assay in IncuCyteu live cell imaging system. Using separate patient samples, miRNA was isolated from placentae from women with and without preeclampsia (n = 2) and miRNA next generation sequencing (miRNAseq) performed. The expression of two miRNAs identified in miRNAseq (miRNA-183–5p and miRNA-203a-3p) were measured in HUVEC cells exposed to 24 h hypoxia (1%) or normoxia (21%) in the presence of MSC conditioned medium (MSC-CM) or MSC-EVs. Results: MSCs isolated from women with preeclampsia demonstrated impaired pro-angiogenic profile compared to MSCs derived from normotensive pregnancies measured by the network length (mm/m2) of HUVECs following 66 h, 72 h, 78 h, 84 h and 90 h of exposure to MSC-CM (n = 3, p = 0.001). The results of miRNAseq identified a number of aberrantly expressed miRNAs including mir-183–5p (logFC = -2.8, p = 0.001) and mir-203a-3p (logFC = -6.7, p = 0.001). Following exposure of HUVECs to hypoxia, mir-183–5p was significantly increased by approximately 8-fold (p = 0.001) whereas mir-203a-3p showed no change in expression. MSC-CM and MSC-EVs were both capable of ameliorating this increase in mir-183–5p as a result of hypoxia (p = 0.01, MSC-CM; p = 0.001, MSC-EVs). Conclusions: In patients with preeclampsia, MSCs show impaired angiogenic function, potentially leading to inappropriate placental development and angiogenesis in pregnancy. Administration of healthy MSCs or associated MSC-EVs could have a therapeutic potential in the treatment of preeclampsia and the mechanism could involve novel mir-183–5p as a treatment target.
Relationships Between Time-at-Bedside During Hospital Ward Rounds, Clinician–Patient Agreement, and Patient Experience
Ratelle, John T. , Herberts, Michelle , Miller, Donna , Kumbamu, Ashok , Lawson, Donna K. , Beckman, Thomas J. , Lawson, Donna, Polley, Eric, Miller, Donna M , Polley, Eric C.

Mayo Clinic

Journal of Patient Experience | April 9, 2021 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/23743735211008303 | PMID 34179432 Get It

Hospital medicine ward rounds are often conducted away from patients’ bedsides, but it is unknown if more time-at-bedside is associated with improved patient outcomes. Our objective is to measure the association between “time-at-bedside,” patient experience, and patient–clinician care agreement during ward rounds. Research assistants directly observed medicine services to quantify the amount of time spent discussing each patient’s care inside versus outside the patient’s room. “Time-at-bedside” was defined as the proportion of time spent discussing a patient’s care in his or her room. Patient experience and patient–clinician care agreement both were measured immediately after ward rounds. Results demonstrated that the majority of patient and physicians completely agreement on planned tests (66.3%), planned procedures (79.7%), medication changes (50.6%), and discharge location (66.9%), but had no agreement on the patient’s main concern (74.4%) and discharge date (50.6%). Time-at-bedside was not correlated with care agreement or patient experience ( P > .05 for all comparisons). This study demonstrates that spending more time at the bedside during ward rounds, alone, is insufficient to improve patient experience.
A Taxonomic Review of Patient Complaints in Adult Hospital Medicine
Eliáš, Richard , Siddiqui, Mustaqeem , Coons, Trevor J. , Meyerhofer, Cindy A, Pretzman, Holly J, Greig, Hope E, Stevens, Sheila K., Burton, M. Caroline , Elias, Richard M , Siddiqui, Mustaqeem A , Coons, Trevor , Fischer, Karen M.

Mayo Clinic

Journal of Patient Experience | April 9, 2021 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/23743735211007351 | PMID 34179414 Get It

Previous studies show that patient complaints can identify gaps in quality of care, but it is difficult to identify trends without categorization. We conducted a review of complaints relating to admissions on hospital internal medicine (HIM) services over a 26-month period. Data were collected on person characteristics and key features of the complaint. The complaints were also categorized into a previously published taxonomy. Seventy-six unsolicited complaints were identified, (3.5 per 1000 hospital admissions). Complaints were more likely on resident services. The mean duration between encounter and complaint was 18 days, and it took an average of 12 days to resolve the complaint. Most patients (59%) had a complaint in the Relationship domain. Thirty-nine percent of complaints mentioned a specific clinician. When a clinician was mentioned, complaints regarding communication and humaneness predominated (68%). The results indicate that the efforts to reduce patient complaints in HIM should focus on the Relationships domain.
Teaching geriatrics during the COVID ‐19 pandemic: Aquifer Geriatrics to the rescue
Ramaswamy, Ravishankar , Denson, Kathryn , Sehgal, Mandi , Syed, Quratulain , Powers, Becky , Schwartz, Andrea Wershof , Leipzig, Rosanne M. , Gleason, Lauren J. , Shah, Amit A, Sehgal, Mandi , Schwartz, Andrea Wershof , Ramaswamy, Ravishankar , Powers, Becky B , Shah, Amit , Syed, Quratulain

Mayo Clinic

Journal of the American Geriatrics Society | April 9, 2021 | Volume: 69 | Issue: 7 | Pages: 1740-1742

10.1111/jgs.17169 | PMID 33834476 Get It

The Society for Obstetric Anesthesia and Perinatology Coronavirus Disease 2019 Registry: An Analysis of Outcomes Among Pregnant Women Delivering During the Initial Severe Acute Respiratory Syndrome Coronavirus-2 Outbreak in the United States
Bateman, Brian T. , Kjaer, Klaus, Spence, Nicole Z. , Toledano, Roulhac D. , Grant, Gilbert, Madden, Hannah E., Lynde, Grant C. , Beilin, Yaakov, Kodali, Bhavani Shankar , Bharadwaj, Shobana , Prabhu, Malavika, Gonzales, Nikolai Y., Leffert, Lisa , Katz, Daniel , Kjaer, Klaus, Turner, Dana P. , Habib, Ashraf S. , George, Ronald B. , Butwick, Alexander J. , Minehart, Rebecca D. , Houle, Timothy T. , Sharpe, Emily E. , Farber, Michaela Kristina , Palanisamy, Arvind , Landau, Ruth

Mayo Clinic

Anesthesia & Analgesia | April 8, 2021 | Volume: 133 | Issue: 2 | Pages: 462-473

10.1213/ane.0000000000005592 | PMID 33830956 Get It

BACKGROUND: Early reports associating severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with adverse pregnancy outcomes were biased by including only women with severe disease without controls. The Society for Obstetric Anesthesia and Perinatology (SOAP) coronavirus disease 2019 (COVID-19) registry was created to compare peripartum outcomes and anesthetic utilization in women with and without SARS-CoV-2 infection delivering at institutions with widespread testing. METHODS: Deliveries from 14 US medical centers, from March 19 to May 31, 2020, were included. Peripartum infection was defined as a positive SARS-CoV-2 polymerase chain reaction test within 14 days of delivery. Consecutive SARS-CoV-2–infected patients with randomly selected control patients were sampled (1:2 ratio) with controls delivering during the same day without a positive test. Outcomes were obstetric (eg, delivery mode, hypertensive disorders of pregnancy, and delivery <37 weeks), an adverse neonatal outcome composite measure (primary), and anesthetic utilization (eg, neuraxial labor analgesia and anesthesia). Outcomes were analyzed using generalized estimating equations to account for clustering within centers. Sensitivity analyses compared symptomatic and asymptomatic patients to controls. RESULTS: One thousand four hundred fifty four peripartum women were included: 490 with SARS-CoV-2 infection (176 [35.9%] symptomatic) and 964 were controls. SARS-CoV-2 patients were slightly younger, more likely nonnulliparous, nonwhite, and Hispanic than controls. They were more likely to have diabetes, obesity, or cardiac disease and less likely to have autoimmune disease. After adjustment for confounders, individuals experiencing SARS-CoV-2 infection exhibited an increased risk for delivery <37 weeks of gestation compared to controls, 73 (14.8%) vs 98 (10.2%) (adjusted odds ratio [aOR], 1.47; 95% confidence interval [CI], 1.03–2.09). Effect estimates for other obstetric outcomes and the neonatal composite outcome measure were not meaningfully different between SARS-CoV-2 patients versus controls. In sensitivity analyses, compared to controls, symptomatic SARS-CoV-2 patients exhibited increases in cesarean delivery (aOR, 1.57; 95% CI, 1.09–2.27), postpartum length of stay (aOR, 1.89; 95% CI, 1.18–2.60), and delivery <37 weeks of gestation (aOR, 2.08; 95% CI, 1.29–3.36). These adverse outcomes were not found in asymptomatic women versus controls. SARS-CoV-2 patients (asymptomatic and symptomatic) were less likely to receive neuraxial labor analgesia (aOR, 0.52; 95% CI, 0.35–0.75) and more likely to receive general anesthesia for cesarean delivery (aOR, 3.69; 95% CI, 1.40–9.74) due to maternal respiratory failure. CONCLUSIONS: In this large, multicenter US cohort study of women with and without peripartum SARS-CoV-2 infection, differences in obstetric and neonatal outcomes seem to be mostly driven by symptomatic patients. Lower utilization of neuraxial analgesia in laboring patients with asymptomatic or symptomatic infection compared to patients without infection requires further investigation.